1. Home
  2. PHAT

PHAT

Phathom Pharmaceuticals Inc.

Logo Phathom Pharmaceuticals Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-18-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.

Founded: N/A Country:
United States
United States
Employees: N/A City: FLORHAM PARK
Market Cap: 586.4M IPO Year: 2019
Target Price: $21.33 AVG Volume (30 days): 911.6K
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -3.93 EPS Growth: N/A
52 Week Low/High: $6.07 - $17.02 Next Earning Date: 05-08-2024
Revenue: $682,000 Revenue Growth: N/A
Revenue Growth (this year): 6602.49% Revenue Growth (next year): 287.50%

Share on Social Networks: